Grand Pharmaceutical Group Dirección

Dirección controles de criterios 3/4

El CEO de Grand Pharmaceutical Group es Chao Zhou , nombrado en Jun 2021, tiene una permanencia de 3.42 años. compensación anual total es HK$1.87M, compuesta por 90.8% salario y 9.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.01% de las acciones de la empresa, por valor de €196.66K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 3.4 años, respectivamente.

Información clave

Chao Zhou

Chief Executive Officer (CEO)

HK$1.9m

Compensación total

Porcentaje del salario del CEO	90.8%
Permanencia del CEO	3.4yrs
Participación del CEO	0.01%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chao Zhou en comparación con los beneficios de Grand Pharmaceutical Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	HK$2b
Mar 31 2024	n/a	n/a	HK$2b
Dec 31 2023	HK$2m	HK$2m	HK$2b

Compensación vs. Mercado: La compensación total de Chao($USD240.63K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD1.65M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Chao con los resultados de la empresa.

CEO

Chao Zhou (34 yo)

3.4yrs

Permanencia

HK$1,873,000

Compensación

Mr. Chao Zhou serves as Chief Executive Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 01, 2021 and serves as its Ex...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Weikun Tang	Executive Chairman	3.4yrs	HK$2.89m	0.021% € 404.8k
Chao Zhou	CEO & Executive Director	3.4yrs	HK$1.87m	0.010% € 196.7k
Guang Yang	Executive Director	1.4yrs	HK$25.00k	sin datos
Liu Hu	Investor Relations Director	no data	sin datos	sin datos
Chit Lam	Executive Director	less than a year	sin datos	0.017% € 320.6k
Tin Chung Foo	Company Secretary	13.2yrs	sin datos	sin datos
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	sin datos	sin datos
Xiaojie Chen	Vice President	no data	sin datos	sin datos

3.4yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MX6A se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Weikun Tang	Executive Chairman	3.4yrs	HK$2.89m	0.021% € 404.8k
Chao Zhou	CEO & Executive Director	1.4yrs	HK$1.87m	0.010% € 196.7k
Guang Yang	Executive Director	1.4yrs	HK$25.00k	sin datos
Chit Lam	Executive Director	less than a year	sin datos	0.017% € 320.6k
Xiaofeng Shi	Chairman of Grand Pharm (China)	no data	sin datos	sin datos
Tosi Wan So	Independent Non-Executive Director	19.7yrs	HK$180.00k	sin datos
Yebi Hu	Independent Non-Executive Director	5.9yrs	HK$60.00k	sin datos
Geng Pei	Independent Non-Executive Director	13.5yrs	HK$100.00k	sin datos
Guofan Xie	Director of Grand Pharm (China)	30.8yrs	sin datos	sin datos
Zhang Bangguo	Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited	no data	sin datos	sin datos
Li Xing	Non-Executive Director	less than a year	sin datos	sin datos

3.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de MX6A se considera experimentada (3.4 años de antigüedad promedio).

Grand Pharmaceutical Group Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

Grand Pharmaceutical Group Limited Announces Executive Changes

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought €44k worth of stock

Less than half of directors are independent

Recent updates

Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

New minor risk - Share price stability

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Executive Chairman recently bought €44k worth of stock

Dividend of HK$0.26 announced

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022)

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.8% yield

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021)

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA

Less than half of directors are independent

First half 2022 earnings released

Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022

Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA

Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022

Less than half of directors are independent

Executive Director recently bought €64k worth of stock

Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 21% undervalued after recent price drop

Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020)

China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million.

Less than half of directors are independent

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo